Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

Umbleja T, Zafar MU, McCallum S, Gattu AK, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Currier JS, Sponseller CA, Diggs MR, Chu SM, Lu[...]

Counseling Female Thyroid Cancer Patients on Radioactive Iodine and Fertility

Leung AM, Brent GA, Larson SM, Osborne JR, Flavell RR, Ringel MD, Sosa JA. Counseling Female Thyroid Cancer Patients on Radioactive Iodine and Fertility. Thyroid.[...]

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation,[...]